A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

Tirzepatide 60mg
Dual GLP-1 / GIP Incretin Agonist — 60mg Presentation

Compound Specifications
Tirzepatide 60mg
Dual GLP-1 / GIP Incretin Agonist — 60mg Presentation
Tirzepatide 60mg is a maximum-strength dual GIP/GLP-1 receptor co-agonist presented in a 3mL vial for physician-directed advanced metabolic protocols.
Maximally engages dual GIP and GLP-1 incretin receptors, enhancing beta-cell sensitivity, supporting adipose lipid metabolism, and suppressing appetite signaling.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administered once weekly subcutaneously, titrated under physician direction to the 60mg presentation.
Frequently Asked Clinical Questions
Who is the 60mg presentation intended for?
The 60mg presentation is intended for patients who have progressed through a physician-guided titration and require the highest-strength compounded presentation.